Daiichi Offer For Ranbaxy Oversubscribed, Canadians Make Demands
This article was originally published in PharmAsia News
Executive Summary
Japan's Daiichi Sankyo plans to give back some of the shares it bought in India's Ranbaxy Laboratories after learning the tender offer for another 20 percent stake was oversubscribed. The firms, still awaiting Indian government approval for the merger, also were hit by a Canadian government demand that Ranbaxy's Canadian division report on how it plans to respond to a U.S. FDA ban on 30 of its generic drugs. Daiichi already has purchased the shares of Ranbaxy's founding family to give it an additional 34.8 percent share, and the other investors tendered more than 92.5 million shares during the tender offer. (Click here for more
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.